Crinetics Pharmaceuticals Q1 2024 GAAP EPS $(0.93) Misses $(0.81) Estimate, Sales $640.000K Beat $255.556K Estimate
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q1 2024 earnings with a GAAP EPS of $(0.93), missing the $(0.81) estimate, and sales of $640K, beating the $255.556K estimate. This represents a 9.41% increase in losses and a 76.11% decrease in sales from the same period last year.
May 09, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Crinetics Pharmaceuticals reported a larger than expected quarterly loss but exceeded sales forecasts in Q1 2024.
The mixed results with a miss on EPS but a beat on sales could lead to uncertain short-term stock price movements. The significant beat in sales might offset concerns over the increased losses, leading to a neutral impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100